ATE459004T1 - Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung - Google Patents

Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung

Info

Publication number
ATE459004T1
ATE459004T1 AT05010407T AT05010407T ATE459004T1 AT E459004 T1 ATE459004 T1 AT E459004T1 AT 05010407 T AT05010407 T AT 05010407T AT 05010407 T AT05010407 T AT 05010407T AT E459004 T1 ATE459004 T1 AT E459004T1
Authority
AT
Austria
Prior art keywords
receptor
protein
fprl2
ligand
application
Prior art date
Application number
AT05010407T
Other languages
English (en)
Inventor
Isabelle Migeotte
Marc Parmentier
David Communi
Maryse Brait
Original Assignee
Euroscreen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euroscreen Sa filed Critical Euroscreen Sa
Application granted granted Critical
Publication of ATE459004T1 publication Critical patent/ATE459004T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05010407T 2004-05-14 2005-05-13 Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung ATE459004T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04447122 2004-05-14
EP04447231 2004-10-18

Publications (1)

Publication Number Publication Date
ATE459004T1 true ATE459004T1 (de) 2010-03-15

Family

ID=34982585

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05010407T ATE459004T1 (de) 2004-05-14 2005-05-13 Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung
AT08159325T ATE496304T1 (de) 2004-05-14 2005-05-13 Ligand für den formylpeptidrezeptorähnlichen-2 (fprl2) g protein gekoppelten rezeptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08159325T ATE496304T1 (de) 2004-05-14 2005-05-13 Ligand für den formylpeptidrezeptorähnlichen-2 (fprl2) g protein gekoppelten rezeptor

Country Status (7)

Country Link
US (3) US7582416B2 (de)
EP (2) EP2020604B1 (de)
JP (2) JP4694887B2 (de)
AT (2) ATE459004T1 (de)
CA (2) CA2504920C (de)
DE (2) DE602005026072D1 (de)
DK (2) DK1607745T3 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1447600A (en) * 1998-10-22 2000-05-08 Thomas J. Gardella Bioactive peptides and peptide derivatives of parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp)
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
CA2454275C (en) * 2001-07-23 2012-10-23 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
US7795220B2 (en) * 2003-03-19 2010-09-14 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
WO2005009358A2 (en) 2003-07-17 2005-02-03 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
CA2504920C (en) * 2004-05-14 2014-04-01 Euroscreen S.A. Ligand for g-protein coupled receptor fprl2 and uses thereof
EP2054077A4 (de) * 2006-08-04 2010-10-13 Gen Hospital Corp Polypeptidderivate des parathyroidhormons (pth)
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US20100297621A1 (en) * 2007-06-20 2010-11-25 University Of Utah Research Foundation Use of pre-mrna splicing in platelet cells for the diagnosis of disease
AU2008282805B2 (en) * 2007-08-01 2014-05-01 Chugai Pharmaceutical Co., Ltd. Screening methods using G-protein coupled receptors and related compositions
AU2009324228A1 (en) * 2008-12-04 2011-06-23 Sanofi-Aventis Methods and uses involving Heme binding protein 1
PL2432760T3 (pl) 2009-05-18 2013-12-31 Actelion Pharmaceuticals Ltd Pochodne zmostkowanego spiro[2.4]heptanu jako agoniści receptora alx i/lub fprl2
WO2011073918A2 (en) 2009-12-16 2011-06-23 Actelion Pharmaceuticals Ltd Peptides as modulators of fprl1 and/or fprl2
WO2011143406A2 (en) 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
EP3314255B1 (de) * 2015-06-25 2019-07-31 H. Hoffnabb-La Roche Ag Zellbasierter assay zur bestimmung von antikörpern oder ligandenbindung und funktion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003345A1 (en) 1988-11-18 1990-05-18 Joel F. Habener Camp-responsive transcriptional enhancer binding protein
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US7119190B2 (en) * 1997-04-14 2006-10-10 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors
JP3495987B2 (ja) 1998-07-06 2004-02-09 エーロスクレーン エッス.アー. カルシウム結合レセプタに対するアゴニスト及び/またはアンタゴニストの高処理能率スクリーニング特性表示及び/または用量決定方法
EP1214337A2 (de) * 1999-09-15 2002-06-19 Incyte Genomics, Inc. Proteine die mit zelldifferenzierung assoziiert sind
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP4184875B2 (ja) * 2002-06-14 2008-11-19 武田薬品工業株式会社 新規スクリーニング方法
CA2504920C (en) * 2004-05-14 2014-04-01 Euroscreen S.A. Ligand for g-protein coupled receptor fprl2 and uses thereof

Also Published As

Publication number Publication date
JP2006025787A (ja) 2006-02-02
US20090053739A1 (en) 2009-02-26
US7842795B2 (en) 2010-11-30
DE602005026072D1 (de) 2011-03-03
ATE496304T1 (de) 2011-02-15
DK1607745T3 (da) 2010-06-14
US7659251B2 (en) 2010-02-09
EP1607745A3 (de) 2006-07-26
CA2810292A1 (en) 2005-11-14
EP2020604A1 (de) 2009-02-04
EP1607745B1 (de) 2010-02-24
EP1607745A2 (de) 2005-12-21
CA2810292C (en) 2015-09-29
JP5314061B2 (ja) 2013-10-16
US7582416B2 (en) 2009-09-01
EP2020604B1 (de) 2011-01-19
DE602005019495D1 (de) 2010-04-08
JP4694887B2 (ja) 2011-06-08
US20100009406A1 (en) 2010-01-14
CA2504920A1 (en) 2005-11-14
CA2504920C (en) 2014-04-01
US20060078559A1 (en) 2006-04-13
DK2020604T3 (da) 2011-05-16
JP2011078437A (ja) 2011-04-21

Similar Documents

Publication Publication Date Title
ATE459004T1 (de) Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung
GEP20094629B (en) Nogo receptor binding protein
EP1392359A4 (de) Spezifische bindungsproteine und ihre verwendung
WO2006113602A3 (en) Ascorbate binding peptides
ATE446972T1 (de) Il-1 bindende antikörper und fragmente davon
ATE504599T1 (de) Zur aktivierung von rezeptoren fähige fusionspolypeptide
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
WO2005087811A3 (en) Estrogen receptors and methods of use
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
ECSP055849A (es) Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico
WO2004090103A8 (en) Identification of novel nogo-receptors and methods related thereto

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties